What Proteos does

Proteos, Inc. is a US-based contract research organization (CRO) founded in 2003 in Kalamazoo, Michigan, specializing in custom recombinant protein production services for the biotechnology and pharmaceutical industries. The company operates three validated expression platforms — mammalian (HEK and CHO), baculovirus-mediated insect cell (Sf9 and Tni), and bacterial (E. coli) — and offers an integrated pipeline spanning construct design, gene synthesis, expression, purification, and analytical characterization. Core service lines include protein expression, protein purification with affinity and classical chromatography, recombinant antibody production (full-length IgG and fusion proteins), and assay services (baculovirus titer, thermal shift assay, intact mass via LC ESI-MS, and colorimetric/fluorometric assays). Most recently, the company added SPR and BLI binding assay services and is building an in-house X-ray crystallography capability.

Following its January 2025 acquisition by NanoImaging Services (NIS), Proteos now operates as a wholly-owned subsidiary of a leading US-based cryo-EM CRO, with laboratories co-located to deliver an integrated Gene-to-Structure workflow from target construct through high-resolution cryo-EM structure determination. The company employs between 11 and 50 people and generates revenue through professional-services, quote-based engagements with typical production timelines of 6–10 weeks per project. Customers include enterprise pharmaceutical companies, virtual and mid-sized biotechs, academic researchers, and structural biology groups; named accounts span a Global Pharmaceutical Company (Princeton, NJ), a Global Healthcare Company (Emeryville, CA), and an International Biologics Company (Toronto, ON), alongside academic and physician customers. Distribution is entirely direct via an inside-sales team with a request-quote model and rapid 24–48 hour quote turnaround, supported by content marketing, conference presence (PEGS Boston), and a partnership with The Michael J. Fox Foundation for Parkinson's disease research reagents.

Name

Proteos

Legal name

Proteos, Inc.

Website

https://proteos.com

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

11–50 employees

Short description

Proteos is a US-based contract research organization (CRO) in Kalamazoo, Michigan, providing custom recombinant protein production services — expression, purification, antibody production, and biophysical assays — for biotech, pharmaceutical, and academic clients. It is a wholly-owned subsidiary of NanoImaging Services following its January 2025 acquisition.

Ownership category

akta.pro rank

Product category

Contract Research Services (Biopharmaceutical / Recombinant Protein Production)

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB)

akta.pro secondary industries

Proteomics & Mass Spectrometry Services (HLAGANAB), Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD)

Keywords

• Recombinant protein production
• Contract research organization
• Antibody production services
• Protein expression services
• Protein purification services

Headquarters

HQ city

Kalamazoo

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. Recombinant Protein Production Services: Contract research organization providing custom recombinant protein production services. Services include protein expression, purification, and characterization for biopharma R&D. Pricing is quote-based with comprehensive and transparent quotations. Typical production times are 6-10 weeks including construct design, expression, and purification.
2. Antibody Production Services: Custom recombinant expression and purification of full-length IgG, antibody fragments, and fusion proteins in mammalian cell expression systems. Part of CRO services.
3. Assay Services: Protein assay services including baculovirus titer assay, thermal shift assay, intact mass measurement, colorimetric and fluorometric assays.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

Proteos is a US-based contract research organization providing custom recombinant protein production services to biotech and pharmaceutical R&D teams. The company expresses and purifies proteins across mammalian (HEK/CHO), baculovirus-mediated insect (Sf9/Tni), and bacterial (E. coli) platforms, and complements production with antibody expression, biophysical assays (SPR, BLI, TSA), intact mass analysis, and an integrated Gene-to-Structure pipeline linking production to cryo-EM structure determination through parent NanoImaging Services.

Product overview

Proteos is a US-based Contract Research Organization (CRO) specializing in recombinant protein production services. The company operates as a wholly-owned subsidiary of NanoImaging Services (NIS) with laboratories in Kalamazoo, Michigan. The product portfolio centers on a comprehensive suite of protein production services organized around three core platforms: Protein Expression (mammalian, insect, and bacterial systems), Protein Purification (affinity and classical chromatography), and Antibody Production (recombinant IgG and fusion proteins). These core services are complemented by Assay Services (baculovirus titer, TSA, intact mass, colorimetric/fluorometric assays), SPR and BLI Binding Assays for biophysical characterization, and an integrated Gene-to-Structure Pipeline that connects protein production to cryo-EM structural determination. A new X-ray Crystallography capability is under development to expand the structural biology platform. The company offers expression scales up to 60L for mammalian cells and 40L for insect cells, with typical production timelines of 6-10 weeks.

Differentiator

Problem solved

Functional benefit

Products and services

• Protein Expression Custom recombinant protein expression service using three platforms (mammalian HEK/CHO, baculovirus-mediated insect Sf9/Tni, and bacterial E. coli), bundled with construct design, gene synthesis, and endotoxin-free plasmid DNA isolation. Targeted at biotech and pharma R&D teams needing eukaryotic and prokaryotic expression for drug discovery.
• Mammalian Cell Expression Transient mammalian cell expression using in-house or customer-provided expression vectors in HEK and CHO cell lines. Suitable for complex proteins requiring post-translational modifications, including full-length IgG and antibody fusion proteins.
• Insect Cell Expression Baculovirus-mediated insect cell expression in Sf9 and Tni cell lines. Offers improved post-translational modification capabilities compared to bacterial systems while being more cost-effective than mammalian cells.
• E. coli Expression Bacterial expression system for simple proteins without complex PTM requirements. Cost-effective option for proteins suitable for prokaryotic expression.
• Protein Purification Comprehensive protein purification service combining affinity chromatography (IMAC, Protein A, FLAG, GST) with classical chromatography (ion exchange, HIC, SEC) and customizable analytical packages for purity and quality assessment.
• Protein Analytics Customizable protein analytics services for purity assessment, quality control, intact mass analysis using LC ESI-MS, and characterization of post-translational modifications or chemical adducts.
• Antibody Production Custom recombinant expression and purification of full-length IgG, antibody fragments, and fusion proteins. Capabilities encompass construct design, transient mammalian cell expression using in-house or customer-provided expression vectors, and affinity purification.
• Assay Services Assay services covering baculovirus titer assay, thermal shift assay (TSA), intact mass measurement, colorimetric and fluorometric assays for protein characterization and quality assessment.
• SPR and BLI Binding Assays Label-free biophysical methods that measure binding interactions in real time, extracting association rate (kon), dissociation rate (koff), and equilibrium affinity (KD). Integrated into the Gene-to-Structure pipeline as a pre-cryo-EM checkpoint, with 1-2 week target turnaround supported by a dedicated biophysics team.
• Gene-to-Structure Pipeline Integrated workflow that takes a target from construct design through protein production and biophysical validation (SPR/BLI) to high-resolution cryo-EM structure determination, delivered through the combined Proteos and NanoImaging Services platform.

Quantifiable outcome

• Typical production times of 6-10 weeks including construct design, expression, and purification
• +3 more outcomes

Named customers9 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Two partnerships are on record, tiered core and minor.

• NanoImaging Services (NIS)coreStrategic or Co-development Partner · 10 January 2025Proteos was acquired by NanoImaging Services (NIS), a leading US-based cryo-EM CRO. This strategic partnership combines Proteos' expertise in protein production with NIS's industry-leading imaging and analytical capabilities, creating an integrated structural biology services platform. The acquisition enables an integrated Gene-to-Structure workflow that takes targets from construct design through protein production to high-resolution cryo-EM structure determination.
• The Michael J. Fox FoundationminorStrategic or Co-development Partner · 15 October 2020Proteos partnered with The Michael J. Fox Foundation to provide high-quality protein reagents in support of Parkinson's disease research. These reagents are made available to researchers for a small fee through Proteos, with support from MJFF. This partnership addresses the need for quality research tools in Parkinson's disease research.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• GenScript ProBio: GenScript ProBio is a major contract protein production and biologics services provider offering recombinant protein expression, antibody production, and gene synthesis across multiple host systems, directly comparable to Proteos' core service portfolio.
• Sino Biological: Sino Biological is a Chinese-based CRO that offers custom recombinant protein production, antibody development, and protein analytics services, directly competing with Proteos for biotech and pharma customers needing custom protein work.
• BPS Bioscience: BPS Bioscience provides custom protein production, recombinant enzymes, and assay services for drug discovery, serving a similar biotech and pharma R&D customer base as Proteos.
• ACROBiosystems: ACROBiosystems is a global provider of recombinant proteins, antibodies, and related CRO services for biologics development, with overlapping capabilities in mammalian and insect cell expression and protein characterization.

Broad incumbents

• Bio-Techne: Bio-Techne is a large life sciences tools and services company with protein production and reagents capabilities, including custom recombinant protein services. It is a broader incumbent with a wider catalog and services portfolio than Proteos.
• Eurofins Discovery: Eurofins Discovery is a large CRO network offering protein production, bioanalytical, and drug discovery services across multiple modalities, serving pharma and biotech customers at a much larger scale than Proteos.
• Thermo Fisher Scientific (PPD/Pharma Services): Thermo Fisher offers broad pharmaceutical and life sciences services including custom protein production and biologics development, serving as a large incumbent with global scale that competes for the same large pharma accounts.
• Catalent (Novo Holdings):
• WuXi Biologics: WuXi Biologics is a global biologics CRO/CDMO offering recombinant protein production, antibody development, and bioanalytical services, competing for biotech and pharma customers needing custom protein work.

Emerging players

• Cayman Chemical: Cayman Chemical produces research-grade proteins, antibodies, and biochemical tools, with custom protein production capabilities that overlap with Proteos' service offerings for academic and biotech customers.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/proteos_inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Proteos